A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

NCT03515785 · clinicaltrials.gov ↗
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Revisiting the availability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward.

Conditions

Sponsor

Incyte Biosciences International Sàrl